Abstract
Lower urinary tract symptoms (LUTS) and erectile dysfunction increase with age. Several studies have identified a true association between these two disorders. Basic research studies have shown a significant decrease in the nitric oxide/cyclic guanosine monophosphate pathway with age that leads to decreased relaxation of the bladder wall and prostate and worsening LUTS. In this review article, we will focus on the potential use and clinical significance of phosphodiesterase-5 inhibitors in the treatment of LUTS secondary to benign prostate hyperplasia.
Disclosure
Dr Carrier has received grants/research support from and been on the advisory board or presented for Eli Lilly, Canada-Pfizer, and Canada-Bayer. He has not received any financial gains through this work.